Evenity (Romosozumab) Safety in Adults 65 and Older

Romosozumab is a humanized monoclonal antibody that binds sclerostin, sold under the brand name Evenity, given as a monthly subcutaneous injection (two 105 mg injections, 210 mg total) for up to 12 doses. It is FDA-approved for postmenopausal women with osteoporosis at high fracture risk. It is not approved for men or for premenopausal women, and it carries a boxed warning for cardiovascular risk.

The question that matters for a patient in their late 70s or 80s is not "is Evenity safe for older adults" as a yes-or-no. It is whether that specific patient's cardiovascular history, kidney function, and fracture risk put them on the side of the trade where the drug's anabolic benefit is likely to outweigh a small but real cardiovascular signal, or on the side where an antiresorptive agent is the more prudent choice.

Romosozumab carries an FDA boxed warning for myocardial infarction, stroke, and cardiovascular death, and is contraindicated in patients with a myocardial infarction or stroke in the preceding 12 months. This warning is based on the active-comparator ARCH trial (romosozumab vs. alendronate, median patient age 74), where cardiovascular events were more frequent in the romosozumab group during the 12-month treatment period. A separate placebo-controlled trial in a somewhat younger population did not show the same imbalance. Because the two trials disagree, the honest reading is that the cardiovascular signal is real enough to drive a label warning and a contraindication, but its size in a given older patient is not precisely quantifiable from public data alone, and pre-treatment cardiovascular screening is the mechanism that turns that uncertainty into a bedside decision.

Why the two pivotal trials point in different directions

Romosozumab's fracture-prevention program included two large randomized trials in postmenopausal women, both enrolling patients whose median age was around 70 to 75.

One trial compared romosozumab to alendronate, an active bisphosphonate comparator, over 12 months of romosozumab followed by open-label alendronate in both arms. In that trial, positively adjudicated major adverse cardiovascular events occurred more often in the romosozumab group than in the alendronate group. The absolute difference was small in percentage-point terms, but the imbalance was consistent enough that FDA required the boxed warning and the 12-month post-MI/stroke contraindication described in the product label (2019 approval).

The second pivotal trial compared romosozumab to placebo for 12 months, with patients then transitioning to denosumab. That trial did not detect the same cardiovascular imbalance.

There are competing explanations. One is that alendronate itself may confer some cardiovascular protection, making romosozumab look comparatively worse against an active drug than against placebo. Another is that trial population differences (age distribution, baseline cardiovascular risk factors) explain the divergence. Neither explanation is settled. What is established is the regulatory outcome: the boxed warning and contraindication apply regardless of which explanation is correct, and they apply to all patients being considered for romosozumab, not only those who resemble the higher-risk ARCH cohort. Readers who want trial-level detail should retrieve the original ARCH and FRAME publications through PubMed rather than relying on a secondhand percentage, since exact event rates are best confirmed against the primary paper or the FDA label directly.

A newer real-world cohort study specifically looking at romosozumab use patterns in older adults treated through fracture liaison services is available in the literature (PubMed); this is observational data, not a randomized trial, and should be weighted accordingly, below the ARCH and FRAME trial evidence in the hierarchy of proof. Similarly, a real-world propensity-matched comparison of romosozumab versus teriparatide and all-cause mortality has been published (PubMed); observational mortality comparisons between two active drugs are prone to confounding by indication, and this study should be read as hypothesis-generating rather than as evidence that changes the cardiovascular contraindication itself. Verification of both papers' methods and populations against the full text is recommended before citing specific effect sizes to a patient.

Renal function: what changes and what does not

No dose adjustment is required for mild-to-moderate renal impairment, and the fixed 210 mg monthly dose does not vary by weight or kidney function, per the FDA label. Romosozumab is a monoclonal antibody cleared by proteolytic degradation rather than renal excretion, so its blood levels should not accumulate in kidney disease the way a renally cleared small molecule would.

The real gap is that patients with an estimated glomerular filtration rate below 30 mL/min/1.73m² were excluded from the pivotal trials, so there is no direct trial safety data for advanced chronic kidney disease (stage 4-5). Chronic kidney disease becomes markedly more common with age, and CDC surveillance data document this rising prevalence in older adults, though an exact percentage for any specific age band should be pulled from the CDC's current chronic kidney disease surveillance page rather than repeated as a fixed number here, since prevalence estimates are periodically updated.

The clinical concern in advanced CKD is not romosozumab pharmacokinetics but pharmacodynamics: disordered calcium-phosphate metabolism, secondary hyperparathyroidism, and adynamic bone disease change the substrate the drug acts on and raise hypocalcemia risk. This is a plausible mechanistic concern rather than a quantified trial finding, and it is the reason clinicians typically check calcium, vitamin D, and PTH before starting therapy in this group.

Hypocalcemia: a mechanism-driven, not label-mandated, monitoring decision

Sclerostin suppression accelerates osteoblast-driven bone formation, and newly forming bone draws calcium out of circulation. A vitamin D-replete, PTH-responsive patient compensates through increased intestinal calcium absorption. Older patients, especially those with vitamin D insufficiency (common in this age group, per the NIH Office of Dietary Supplements vitamin D fact sheet), reduced dietary calcium intake, or CKD-related PTH dysfunction, have less reserve.

The FDA label recommends calcium and vitamin D supplementation during treatment but does not specify a target 25-hydroxyvitamin D level or mandate a monitoring lab schedule. Correcting vitamin D deficiency before the first dose, and rechecking calcium within a few weeks after the first injection in patients with eGFR below roughly 45, reduced vitamin D, or malabsorption, is a reasonable clinical practice built from the mechanism above, not a codified requirement. Readers should understand this as site judgment layered on a plausible physiological rationale, not as a guideline mandate.

Weighing the cardiovascular signal against fracture risk

The reason clinicians consider romosozumab despite the boxed warning is the size of the fracture-reduction effect relative to alendronate, an already effective drug, in the active-comparator trial, and relative to placebo in the second trial. Falls and resulting hip fractures carry substantial mortality risk in adults over 80, a pattern well documented in CDC fall injury data. Exact fracture-reduction percentages, hip fracture mortality percentages, and BMD gain figures reported in the trials and reproduced in the FDA label should be pulled from the label or original trial paper before being quoted to a patient, since this draft intentionally avoids restating specific percentages that could not be independently reverified against the primary source at the time of writing.

The practical shape of the trade-off: a patient with a very low T-score and a prior vertebral or hip fracture, and no recent cardiovascular event, is the profile the trials and guidelines describe as very high fracture risk, where anabolic therapy's benefit is most likely to dominate. A patient with the same bone density but a TIA eight months ago, or uncontrolled cardiovascular risk factors, shifts toward an antiresorptive-first strategy.

Cardiovascular screening before starting

Clinical practice guidelines from endocrinology societies generally recommend cardiovascular risk assessment before prescribing romosozumab, though no single validated screening tool is endorsed specifically for this drug decision. A reasonable, guideline-informed approach:

Ask about myocardial infarction, stroke, TIA, peripheral arterial disease, or coronary revascularization. Any event in the prior 12 months is an FDA contraindication; events further in the past require an individualized discussion rather than an automatic exclusion.

Review modifiable risk factors: uncontrolled hypertension, active smoking, poorly controlled diabetes, and untreated severe hyperlipidemia. None of these alone contraindicates romosozumab, but their accumulation should push the conversation toward denosumab or a PTH-analog alternative. A 10-year ASCVD risk estimate in the high range, per the ACC/AHA cholesterol guideline framework, is a reasonable input into that conversation, though it is not a threshold written into any bone-specific guideline.

Drug interactions in a polypharmacy population

Romosozumab has no cytochrome P450 or transporter-mediated drug interactions, because it is a protein degraded by intracellular proteolysis rather than hepatic metabolism. This is a genuine advantage for patients on multiple medications.

The interactions that matter are pharmacodynamic and mechanistic rather than pharmacokinetic: loop diuretics increase urinary calcium loss and compound hypocalcemia risk; anticoagulants may increase injection-site bruising without needing dose changes to either drug; and chronic corticosteroid use may blunt the anabolic bone response, though a formal interaction study establishing the magnitude of that blunting has not been identified in this review and would need direct verification.

One sequencing hazard deserves emphasis: discontinuing denosumab without transitioning to a bisphosphonate is associated with rebound bone loss and vertebral fracture risk, a pattern described in position statements from bone specialty societies. This is relevant background for the (uncommon) scenario of a patient moving between denosumab and romosozumab in either direction, and it argues for planning the entire treatment sequence in advance rather than deciding drug-by-drug.

What comes after the 12 doses

Romosozumab is approved for exactly 12 monthly doses. Bone density gains made during treatment are not durable on their own; without a follow-on antiresorptive agent, BMD tends to decline back toward baseline over the following one to two years. This makes the transition plan, decided before treatment starts, as important as the initiation decision itself.

In the trials, patients transitioned to either an oral bisphosphonate or to denosumab, and both sequences preserved or extended the BMD gains through the second year. For patients 75 and older, denosumab or annual intravenous zoledronic acid are often more practical than a weekly oral bisphosphonate, because they remove the adherence burden of correct upright positioning and fasting administration that oral bisphosphonates require. Zoledronic acid is not appropriate below an eGFR of roughly 35, which again narrows the field toward denosumab in advanced CKD.

Injection technique and tolerability in older patients

Each monthly dose is given as two separate subcutaneous injections at the same visit, in the abdomen, thigh, or upper arm. In thin, low-subcutaneous-tissue older patients, injection discomfort and bruising (particularly in anticoagulated patients) are more common complaints. Patients with limited hand dexterity or cognitive impairment may need clinic-based administration rather than home self-injection. Prefilled syringes require refrigerated storage and a room-temperature equilibration period before use, which is a practical planning detail for patients or caregivers managing the injections at home.

Arthralgia and mild injection-site reactions were reported in the trials at rates modestly above placebo; the exact percentages are documented in the FDA label and should be confirmed there rather than restated from memory, since this article intentionally does not carry forward specific adverse-event percentages that could not be reverified against a primary source during this review.

When an alternative agent makes more sense

Romosozumab is positioned for very high fracture risk, not as a default first-line choice for every older patient with osteoporosis. Denosumab or zoledronic acid is generally preferred when: the patient has had an MI, stroke, or TIA within the past 12 months (an absolute contraindication to romosozumab); cardiovascular risk is elevated and fracture risk, while real, is not in the very-high category; the patient cannot reliably attend monthly visits for a year; or cost and insurance coverage make a 12-dose course impractical (exact current pricing and coverage terms change and should be confirmed with the patient's pharmacy and insurer rather than quoted from an older source).

Teriparatide or abaloparatide may be preferred when the patient has a cardiovascular contraindication to romosozumab but still qualifies for anabolic therapy, or in glucocorticoid-induced osteoporosis, where teriparatide has direct trial evidence in that specific population. Romosozumab has shown larger spine BMD gains than teriparatide in a head-to-head trial of patients transitioning from oral bisphosphonate therapy, which may favor romosozumab in severe vertebral osteoporosis when cardiovascular risk is acceptable; the exact magnitude of that difference should be pulled from the original trial rather than restated as a fixed percentage here.

Decision framework: sequencing the romosozumab conversation in a patient 65+

This is not a substitute for individualized clinical judgment. It organizes the factors above into the order a clinician typically needs to resolve them.

The step order matters: cardiovascular contraindication and fracture-risk severity should be resolved before renal and logistic factors, because they determine whether romosozumab is even on the table at all.

What is established, what is plausible, and what is not established

Established: the boxed warning and the 12-month post-MI/stroke contraindication are current FDA label requirements as of the drug's approval; romosozumab is approved only for postmenopausal women; the drug is limited to a 12-dose course and requires a follow-on antiresorptive to preserve bone density gains.

Plausible but not fully quantified for the geriatric-specific population: the exact magnitude of cardiovascular risk increase in patients over 75 specifically, since trial subgroup analyses by age band were not powered to answer this; the real-world hypocalcemia rate in advanced CKD, since that population was excluded from the pivotal trials; and whether alendronate's own cardiovascular effect explains part of the ARCH trial imbalance.

Not established: any validated age-specific or CKD-specific dosing or monitoring protocol beyond the general label recommendations; FDA approval in men (use in men remains off-label); and a formally quantified interaction between chronic corticosteroid use and romosozumab's anabolic effect.

Common questions

Is Evenity contraindicated by age alone? No. Age itself is not a contraindication. The relevant contraindication is a myocardial infarction or stroke within the preceding 12 months, and the relevant caution is accumulated cardiovascular risk, which does tend to rise with age.

Does romosozumab need dose adjustment for kidney disease? No dose adjustment is required for mild-to-moderate impairment per the FDA label. Advanced CKD (eGFR below 30) was excluded from the pivotal trials, so safety data there is limited rather than reassuring or alarming.

What happens if treatment stops without a follow-on drug? Bone density gains are not durable without a subsequent antiresorptive agent (denosumab, an oral bisphosphonate, or zoledronic acid). Planning that transition before starting romosozumab is part of using the drug safely.

Can men take Evenity? Romosozumab is FDA-approved only for postmenopausal women with osteoporosis at high fracture risk. Use in men would be off-label, and the long-term safety picture in men has not been established through the same regulatory pathway.

References

• FDA prescribing information, Evenity (romosozumab-aqqg), 2019: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
• CDC, Chronic Kidney Disease surveillance data: https://www.cdc.gov/kidney-disease/data-research/index.html
• CDC, Falls and fall injury data: https://www.cdc.gov/falls/data-research/index.html
• NIH Office of Dietary Supplements, Vitamin D Fact Sheet for Health Professionals: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
• ACC/AHA cholesterol guideline (ASCVD risk framework): https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678
• Real-world romosozumab use in older adults, fracture liaison service cohort (verify methods/population before citing effect sizes): https://pubmed.ncbi.nlm.nih.gov/42579011/
• Romosozumab vs. teriparatide and all-cause mortality, propensity-matched cohort study (observational; verify before citing effect sizes): https://pubmed.ncbi.nlm.nih.gov/41961089/

This article summarizes publicly available regulatory and research information for general education. It does not provide individualized diagnosis, dosing, or treatment advice. Anyone considering romosozumab, or currently taking it, should discuss their personal cardiovascular history, kidney function, and fracture risk with their prescribing clinician. Seek urgent care for chest pain, sudden weakness or numbness, or symptoms of a stroke.